In the Last weeks we saw the announcement of the pricing of BG-12 at about $55,000 p.a. but as we also heard the dimethyl fumarate is cheap as chips. I could buy 100g of non-clinical grade chemical for £34 = 200 days worth of treatment.
As one of the readers pointed about drug pricing out the price that pharma charge no longer has anything to do with the cost of manufacture of the drug, or cost of development, which is not cheap and pharma need to recoup costs. However there is fumaderm, which will be considerably cheaper than the Biogen drug.
A cheaper alternative to expensive DMT could save the NHS millions.
Then there is the issue of statins, which is out of patent, will a company develop them for MS?
If academics invent drugs they will at some point become pharmaceutical industry or get some pharmaceutical company involvement, but should they start the process. I have views on this what are your views?